<?xml version='1.0' encoding='utf-8'?>
<document id="27450623"><sentence text="Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs."><entity charOffset="25-34" id="DDI-PubMed.27450623.s1.e0" text="vitamin K" /></sentence><sentence text="Atrial fibrillation (AF) is a frequent cause of stroke" /><sentence text=" Secondary prophylaxis by oral anticoagulants (OAC) is recommended after stroke in AF-patients" /><sentence text=" OAC can be achieved by vitamin-K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) like dabigatran, rivaroxaban, apixaban or edoxaban"><entity charOffset="60-69" id="DDI-PubMed.27450623.s4.e0" text="vitamin K" /><entity charOffset="114-124" id="DDI-PubMed.27450623.s4.e1" text="dabigatran" /><entity charOffset="126-137" id="DDI-PubMed.27450623.s4.e2" text="rivaroxaban" /><entity charOffset="139-147" id="DDI-PubMed.27450623.s4.e3" text="apixaban" /><entity charOffset="151-159" id="DDI-PubMed.27450623.s4.e4" text="edoxaban" /><pair ddi="false" e1="DDI-PubMed.27450623.s4.e0" e2="DDI-PubMed.27450623.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27450623.s4.e0" e2="DDI-PubMed.27450623.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27450623.s4.e0" e2="DDI-PubMed.27450623.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27450623.s4.e0" e2="DDI-PubMed.27450623.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27450623.s4.e0" e2="DDI-PubMed.27450623.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27450623.s4.e1" e2="DDI-PubMed.27450623.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27450623.s4.e1" e2="DDI-PubMed.27450623.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27450623.s4.e1" e2="DDI-PubMed.27450623.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27450623.s4.e1" e2="DDI-PubMed.27450623.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27450623.s4.e2" e2="DDI-PubMed.27450623.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27450623.s4.e2" e2="DDI-PubMed.27450623.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27450623.s4.e2" e2="DDI-PubMed.27450623.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27450623.s4.e3" e2="DDI-PubMed.27450623.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27450623.s4.e3" e2="DDI-PubMed.27450623.s4.e4" /></sentence><sentence text=" Seizures are frequent after stroke, and antiepileptic drugs (AEDs) are indicated" /><sentence text=" The review, based on a literature research, aims to give an overview about pharmacokinetic knowledge and clinical data about drug-drug interactions (DDIs) between NOACs and AED" /><sentence text=" Carbamazepine, levetiracetam, phenobarbital, phenytoin and valproic acid might decrease the effect of NOACs by inducing P-glycoprotein (P-gp) activity"><entity charOffset="1-14" id="DDI-PubMed.27450623.s7.e0" text="Carbamazepine" /><entity charOffset="16-29" id="DDI-PubMed.27450623.s7.e1" text="levetiracetam" /><entity charOffset="31-44" id="DDI-PubMed.27450623.s7.e2" text="phenobarbital" /><entity charOffset="46-55" id="DDI-PubMed.27450623.s7.e3" text="phenytoin" /><entity charOffset="60-73" id="DDI-PubMed.27450623.s7.e4" text="valproic acid" /><pair ddi="false" e1="DDI-PubMed.27450623.s7.e0" e2="DDI-PubMed.27450623.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27450623.s7.e0" e2="DDI-PubMed.27450623.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27450623.s7.e0" e2="DDI-PubMed.27450623.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27450623.s7.e0" e2="DDI-PubMed.27450623.s7.e3" /><pair ddi="false" e1="DDI-PubMed.27450623.s7.e0" e2="DDI-PubMed.27450623.s7.e4" /><pair ddi="false" e1="DDI-PubMed.27450623.s7.e1" e2="DDI-PubMed.27450623.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27450623.s7.e1" e2="DDI-PubMed.27450623.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27450623.s7.e1" e2="DDI-PubMed.27450623.s7.e3" /><pair ddi="false" e1="DDI-PubMed.27450623.s7.e1" e2="DDI-PubMed.27450623.s7.e4" /><pair ddi="false" e1="DDI-PubMed.27450623.s7.e2" e2="DDI-PubMed.27450623.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27450623.s7.e2" e2="DDI-PubMed.27450623.s7.e3" /><pair ddi="false" e1="DDI-PubMed.27450623.s7.e2" e2="DDI-PubMed.27450623.s7.e4" /><pair ddi="false" e1="DDI-PubMed.27450623.s7.e3" e2="DDI-PubMed.27450623.s7.e3" /><pair ddi="false" e1="DDI-PubMed.27450623.s7.e3" e2="DDI-PubMed.27450623.s7.e4" /></sentence><sentence text=" Carbamazepine, oxcarbazepine, phenytoin, phenobarbital and topiramate might decrease the effect of NOACs by inducing CYP3A4 activity"><entity charOffset="1-14" id="DDI-PubMed.27450623.s8.e0" text="Carbamazepine" /><entity charOffset="16-29" id="DDI-PubMed.27450623.s8.e1" text="oxcarbazepine" /><entity charOffset="31-40" id="DDI-PubMed.27450623.s8.e2" text="phenytoin" /><entity charOffset="42-55" id="DDI-PubMed.27450623.s8.e3" text="phenobarbital" /><entity charOffset="60-70" id="DDI-PubMed.27450623.s8.e4" text="topiramate" /><pair ddi="false" e1="DDI-PubMed.27450623.s8.e0" e2="DDI-PubMed.27450623.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27450623.s8.e0" e2="DDI-PubMed.27450623.s8.e1" /><pair ddi="false" e1="DDI-PubMed.27450623.s8.e0" e2="DDI-PubMed.27450623.s8.e2" /><pair ddi="false" e1="DDI-PubMed.27450623.s8.e0" e2="DDI-PubMed.27450623.s8.e3" /><pair ddi="false" e1="DDI-PubMed.27450623.s8.e0" e2="DDI-PubMed.27450623.s8.e4" /><pair ddi="false" e1="DDI-PubMed.27450623.s8.e1" e2="DDI-PubMed.27450623.s8.e1" /><pair ddi="false" e1="DDI-PubMed.27450623.s8.e1" e2="DDI-PubMed.27450623.s8.e2" /><pair ddi="false" e1="DDI-PubMed.27450623.s8.e1" e2="DDI-PubMed.27450623.s8.e3" /><pair ddi="false" e1="DDI-PubMed.27450623.s8.e1" e2="DDI-PubMed.27450623.s8.e4" /><pair ddi="false" e1="DDI-PubMed.27450623.s8.e2" e2="DDI-PubMed.27450623.s8.e2" /><pair ddi="false" e1="DDI-PubMed.27450623.s8.e2" e2="DDI-PubMed.27450623.s8.e3" /><pair ddi="false" e1="DDI-PubMed.27450623.s8.e2" e2="DDI-PubMed.27450623.s8.e4" /><pair ddi="false" e1="DDI-PubMed.27450623.s8.e3" e2="DDI-PubMed.27450623.s8.e3" /><pair ddi="false" e1="DDI-PubMed.27450623.s8.e3" e2="DDI-PubMed.27450623.s8.e4" /></sentence><sentence text=" Controversial data - inhibition as well as induction of CYP3A4 - were found about valproic acid"><entity charOffset="83-96" id="DDI-PubMed.27450623.s9.e0" text="valproic acid" /></sentence><sentence text=" The relevance of these DDIs is largely unknown since there are only sporadic case reports available" /><sentence text=" To increase the knowledge about DDIs between NOACs and AEDs we suggest subgroup analyses addressing effects and safety of VKAs versus NOACs in patients with AF on AEDs, in case they have been included in previously completed or still ongoing trials or registries" /><sentence text=" This could be easily feasible and would be desirable in view of the large data already accumulated" /><sentence text="" /></document>